Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aveo Diagnostic Tests Receive US Patents
Aveo said that the patents cover two different diagnostic tests for identifying human patients likely to respond to treatment with tivozanib, company’s selective inhibitor of VEGF receptors 1,
Aveo said that the patents cover two different diagnostic tests for identifying human patients likely to respond to treatment with tivozanib, company’s selective inhibitor of VEGF receptors 1,
Biotivia claimed that Florativia is the world’s first supplement combining both prebiotics and probiotics in one Twist ‘n Shake bottle. According to Florativia its new packaging technology separates
Final adoption of the opinion is expected from the European Commission later this year and subject to it being finally granted, the orphan drug status would trigger a
According to the invention 4460446 patent disclosure, the compounds are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder
Fibrocaps is based on a mixture of two essential blood clotting proteins, fibrinogen and thrombin, and is a dry powder topical tissue sealant in development to stop bleeding
Evotec had entered into a multi-year, multi-target drug discovery alliance with Boehringer Ingelheim in 2004, to jointly identify and develop preclinical development candidates for the treatment of various
The treatment and enrollment in these studies is expected to restart after approval by the local regulatory authorities and ethics committees. The announcement follows a decision by the
Levetiracetam injection is indicated as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy. It is also indicated as adjunctive therapy in the treatment
As per the terms of the agreement, Bayer and OncoMed are expected to develop antibodies, protein therapeutics, and small molecules as potential novel anti-cancer stem cell therapeutics targeting
Brocacef holds stakes in companies from the field of homecare, blistering, formulation and the distribution of non-prescription products with total revenues of around EUR1b. In turn, Celesio receives